Overview

Rifaximin in Patients With Monoclonal Gammopathy

Status:
Recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborator:

The Leukemia and Lymphoma Society

Treatments:

Rifamycins
Rifaximin